J&J asked for opioid marketing data; EU approves Bayer cancer drug;

@FiercePharma: So, if you're not among the 103K people who have already, check it out. Report | Follow @FiercePharma

@EricPFierce: With a market as big as China, you can't let a bribery case scare you away. J&J, Merck to build new plants. More | Follow @EricPFierce

@CarlyHFierce: Tufts University report: 71% of revenue from the top 10 best-selling meds last year came from biotech products. More | Follow @CarlyHFierce

> Chicago authorities have subpoenaed Johnson & Johnson ($JNJ) over its marketing of the Duragesic patch and Nucynta tablet. Story

> The European Commission has approved Bayer's new prostate cancer drug Xofigo. Report

> Sources say Sanofi ($SNY) is close to buying Mumbai-based Elder Pharmaceuticals. Story

> A new report from U.K. consultant Gold Group confirms that the majority of women execs in pharma are in lower-paying jobs. Report

Medical Device News

@FierceMedDev: Trending on FierceMedicalDevices: Report: J&J plans layoffs, revamp to jumpstart diabetes arm. Story | Follow @FierceMedDev

@MarkHFierce: NeuroPace won the FDA's blessing for a neurostimulation implant to treat epilepsy. More | Follow @MarkHFierce

@MichaelGFierce: Next-gen sequencing tech from GenapSys nets $37M round. Item | Follow @MichaelGFierce

> In a blow to Edwards, German court restores Medtronic's right to sell heart valve. Article

> As other IPOs move forward, CardioDx pulls back. More

> Kimberly-Clark seeks to spin off healthcare, medical devices arm. News

Biotech News

@FierceBiotech: Baxter bets $60M on Cell Therapeutics' blood cancer drug. Article | Follow @FierceBiotech

@JohnCFierce: Vanda jumps again as FDA panel smiles on sleep-disorder drug. More | Follow @JohnCFierce

@DamianFierce: ICYMI: Sanofi gets mixed FDA blessing for MS drug Lemtrada. Story | Follow @DamianFierce

@EmilyMFierce: From FierceBiotech Research: Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. Article | Follow @EmilyMFierce

> Catabasis nails $32.4M for triglyceride-busting drug. News

> Zafgen obesity drug scores heavyweight success in PhII trial. More

> Relax, PCSK9ers: FDA won't roadblock blockbusters from Sanofi, Amgen. Story

And Finally... A study by IMS Healthcare Informatics says that more than 90% of consumer mobile healthcare apps are targeted at the wrong demographic and of limited value. Story